title: Does pattern electroretinogram spatial tuning alteration in Parkinson's disease depend on motor disturbances or retinal dopaminergic loss?
abstract: Systemic decrease of dopaminergic cells, such as in Parkinson's disease may produce visual alterations in humans. In order to show possible pattern electroretinogram (PERG) spatial tuning function (STF) alterations due to impaired dopaminergic transmission in humans, we studied a group of Parkinson's disease patients before and during treatment with the dopamine precursor, levodopa, and compared their performances with those of an age-matched control group. Moreover, in order to exclude the possible involvement of motor disabilities to produce PERG alterations, we also investigated PERG responses in post-traumatic parkinsonian patients who exhibited motor abnormalities as a consequence of focal lesions of basal ganglia, in the absence of systemic dopaminergic degeneration. Our results showed a clear decrease of PERG responses in Parkinson's disease patients particularly at medium spatial frequency range (2.7-4.0 cycles/degree) with a substantial preservation of responses at low frequencies. Levodopa therapy reversed these alterations in Parkinson's disease patients, resulting in the recovery of a normal tuning function shape. In contrast to Parkinson's disease, the tuning function appeared to be preserved in post-traumatic parkinsonian patients. Our results clearly establish a relationship between retinal alteration in PD patients and dopaminergic retinal function.
authors.affiliation: I.R.C.C.S. Clinica, S. Lucia, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Peppe
authors.forename: P
authors.initials: P
authors.lastname: Stanzione
authors.forename: M
authors.initials: M
authors.lastname: Pierantozzi
authors.forename: R
authors.initials: R
authors.lastname: Semprini
authors.forename: A
authors.initials: A
authors.lastname: Bassi
authors.forename: A M
authors.initials: AM
authors.lastname: Santilli
authors.forename: R
authors.initials: R
authors.lastname: Formisano
authors.forename: M
authors.initials: M
authors.lastname: Piccolino
authors.forename: G
authors.initials: G
authors.lastname: Bernardi
mesh_terms: D000328:Adult; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D001930:Brain Injuries / Q000150:complications / Q000378:metabolism / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism*; D004569:Electroencephalography; D004596:Electroretinography; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000503:physiopathology*; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology*; D010364:Pattern Recognition, Visual / Q000502:physiology; D010775:Photic Stimulation; D012160:Retina / Q000378:metabolism* / Q000503:physiopathology*; D013028:Space Perception / Q000502:physiology*; D015349:Vision, Monocular / Q000502:physiology
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa; D004298:Dopamine